Nova One Advisor
Global Drug allergy Market Size, Share, Forecast Report, 2020-2027

Global Drug allergy Market Size, Share, Forecast Report, 2020-2027

Status: Published Category: Healthcare Insight Code: 2738 Format: PDF / PPT / Excel

Content

Drug allergy is one of the most common types of allergies. It is the hyper sensitivity of the immune system to drug or medication. Any types of drugs such as prescription, nonprescription or herbal can induce drug allergy. Some common symptoms of the drug allergies are hives, skin rash, itching of the eyes or skin, swelling of the face, lips, or tongue, wheezing, and others. Treatment can relieve and prevent severe reactions.

Increasing awareness about various allergies, the introduction of the new treatment of products and rising demand from emerging markets drives the growth of the global market. New research to prevent drug allergies is another key driver for the market. The global drug allergy market is growing moderately and is expected to continue its growth over the forecast period.

The global drug allergy market is expected to grow at the CAGR of ~5.1% during the forecast period and is estimated to reach USD 4764.0 million by 2023.
Key Players in the Global Drug Allergy Market

Some of the key players in this market: AstraZeneca (UK), Bayer (US), Circassia (US), HAL Allergy Group (the Netherlands), Johnson & Johnson Services, Inc. (US), MAGNA Pharmaceuticals, Inc. (US), Stallergenes Greer (UK), and others.

Segments

The global drug allergy market is segmented on the basis of type, which comprises of immunologic, nonimmunologic, and others. Immunologic allergy is sub-segmented into type I reaction, type II reaction, type III reaction, type IV reaction, and others. The non-immunologic allergy is sub-segmented into predictable, unpredictable, and others. The predictable allergy is further segmented into pharmacologic side effect, secondary pharmacologic side effect, drug toxicity, drug-drug interactions, drug overdose, and others. The unpredictable segment is further sub-segmented into pseudoallergic, idiosyncratic, intolerance, and others.
Sources: European Academy of Allergy and Clinical Immunology, Asthma and Allergy Foundation of America, American Academy of Allergy, Asthma & Immunology, National Center for Biotechnology Information (NCBI), Allergy UK, World Allergy Organization (WAO), Directorate of Industries, annual report, white paper, company presentation

On the basis of diagnosis, the market is segmented into skin tests, blood tests, patch test, and others. The skin test is further segmented into prick or scratch test, intradermal test, and others.

On the basis of treatments, the market is segmented into antihistamines, corticosteroids, treatment of anaphylaxis, withdrawal of the drug, and others. Antihistamines are further sub-segmented into azelastine eyedrops, azelastine nasal sprays, carbinoxamine, cyproheptadine, desloratadine, diphenhydramine, emedastine eyedrops, hydroxyzine, levocabastine eyedrops, levocabastine oral, and others. Corticosteroids is further sub-segmented into topical steroids, inhaled steroids, and others. Inhaled steroids is further segmented into flunisolide, fluticasone furoate, fluticasone propionate, triamcinolone acetonide, beclomethasone dipropionate, budesonide, and others.

On the basis of end user, it is segmented into hospitals & clinics, medical research centers, academic institutes, and others.

  • Insight Code: 2738
  • No. of Pages: 250
  • Format: PDF/PPT/Excel
  • Published: July 2020
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034